Yunlin Ye

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/202931/publications.pdf

Version: 2024-02-01

24	329	840776 11	888059 17
papers	citations	h-index	g-index

34	34	34	466
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer, 2017, 17, 171.	2.6	48
2	Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. OncoImmunology, 2017, 6, e1269047.	4.6	47
3	Motor neuron and pancreas homeoboxÂ1/HLXB9 promotes sustained proliferation in bladder cancer by upregulating CCNE1/2. Journal of Experimental and Clinical Cancer Research, 2018, 37, 154.	8.6	29
4	N6-Methyladenosine Modification of LncRNA DUXAP9 Promotes Renal Cancer Cells Proliferation and Motility by Activating the PI3K/AKT Signaling Pathway. Frontiers in Oncology, 2021, 11, 641833.	2.8	24
5	Split renal function in patients with renal masses: utility of parenchymal volume analysis vs nuclear renal scans. BJU International, 2020, 125, 686-694.	2.5	22
6	Prognostic significance of laterality in renal cell carcinoma: A populationâ€based study from the surveillance, epidemiology, and end results (SEER) database. Cancer Medicine, 2019, 8, 5629-5637.	2.8	20
7	Predicting GFR after radical nephrectomy: the importance of split renal function. World Journal of Urology, 2022, 40, 1011-1018.	2.2	16
8	Infiltrative Renal Masses: Clinical Significance and Fidelity of Documentation. European Urology Oncology, 2021, 4, 264-273.	5.4	15
9	High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer. Aging, 2020, 12, 8728-8741.	3.1	15
10	The Complete Spectrum of Infiltrative Renal Masses: Clinical Characteristics and Prognostic Implications. Urology, 2019, 130, 86-92.	1.0	13
11	Establishment and characterization of a penile cancer cell line, penl1, with a deleterious TP53 mutation as a paradigm of HPV-negative penile carcinogenesis. Oncotarget, 2016, 7, 51687-51698.	1.8	12
12	The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer. World Journal of Urology, 2018, 36, 1191-1200.	2.2	12
13	An improved ileal conduit surgery for bladder cancer with fewer complications. Cancer Communications, 2019, 39, 1-10.	9.2	9
14	Renal Cancer Surgery in Patients without Preexisting Chronic Kidney Diseaseâ€"Is There a Survival Benefit for Partial Nephrectomy?. Journal of Urology, 2019, 201, 1088-1096.	0.4	8
15	Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer. Frontiers in Molecular Biosciences, 2021, 8, 800945.	3.5	8
16	The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma. Cancer Biomarkers, 2017, 19, 207-212.	1.7	6
17	Methylation of STK11 promoter is a risk factor for tumor stage and survival in clear cell renal cell carcinoma. Oncology Letters, 2017, 14, 3065-3070.	1.8	5
18	A Nomogram for Predicting Intraoperative Hemodynamic Instability in Patients With Pheochromocytoma. Frontiers in Endocrinology, 2021, 12, 787786.	3.5	5

#	Article	IF	Citations
19	Extraperitonealization of ileal conduit reduces parastomal hernia after cystectomy and ileal conduit diversion. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 162.e17-162.e23.	1.6	4
20	Optimizing prediction of new-baseline glomerular filtration rate after radical nephrectomy: are algorithms really necessary?. International Urology and Nephrology, 2022, 54, 2537-2545.	1.4	4
21	Transcriptional regulation of E-cadherin by small activating RNA: A new double-stranded RNA. International Journal of Oncology, 2016, 49, 1620-1628.	3.3	3
22	A clinicopathological analysis of adrenal tumors in patients with history of extra-adrenal cancers. BMC Cancer, 2019, 19, 838.	2.6	2
23	The effectiveness of chemotherapy for patients with pT3N0M0 renal pelvic urothelial carcinomas: An inverse probability of treatment weighting comparison using Surveillance, Epidemiology, and End Results data. Cancer Medicine, 2020, 9, 5756-5766.	2.8	2
24	MAP kinase-interacting kinase 1 (MNK1) plays as a tumor suppressor in bladder cancer. Translational Cancer Research, 2020, 9, 2588-2598.	1.0	0